fms-Like Tyrosine Kinase 3
"fms-Like Tyrosine Kinase 3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A receptor tyrosine kinase that is involved in HEMATOPOIESIS. It is closely related to FMS PROTO-ONCOGENE PROTEIN and is commonly mutated in acute MYELOID LEUKEMIA.
Descriptor ID |
D051941
|
MeSH Number(s) |
D08.811.913.696.620.682.725.400.020 D12.776.543.750.060.020 D12.776.624.664.700.114 D23.050.301.264.035.284 D23.101.100.110.284
|
Concept/Terms |
fms-Like Tyrosine Kinase 3- fms-Like Tyrosine Kinase 3
- fms Like Tyrosine Kinase 3
- Fetal Liver Kinase-2
- Fetal Liver Kinase 2
- Fetal Liver Kinase-3
- Fetal Liver Kinase 3
- CD135 Antigen
- Antigen, CD135
- Antigens, CD135
- CD135 Antigens
- Stem Cell Tyrosine Kinase 1
|
Below are MeSH descriptors whose meaning is more general than "fms-Like Tyrosine Kinase 3".
Below are MeSH descriptors whose meaning is more specific than "fms-Like Tyrosine Kinase 3".
This graph shows the total number of publications written about "fms-Like Tyrosine Kinase 3" by people in UAMS Profiles by year, and whether "fms-Like Tyrosine Kinase 3" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2023 | 0 | 2 | 2 | 2021 | 2 | 0 | 2 | 2019 | 0 | 1 | 1 | 2018 | 1 | 0 | 1 | 2015 | 2 | 0 | 2 | 2013 | 1 | 0 | 1 | 2011 | 1 | 0 | 1 | 2010 | 1 | 0 | 1 | 2008 | 0 | 1 | 1 | 2005 | 0 | 1 | 1 | 2004 | 0 | 1 | 1 | 2002 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "fms-Like Tyrosine Kinase 3" by people in Profiles over the past ten years.
-
Wang X, DeFilippis RA, Weldemichael T, Gunaganti N, Tran P, Leung YK, Shah NP, Li HY. An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L. Eur J Med Chem. 2024 Jan 15; 264:115977.
-
Wang X, DeFilippis RA, Leung YK, Shah NP, Li HY. N-(3-Methoxyphenyl)-6-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl)pyridin-2-amine is an inhibitor of the FLT3-ITD and BCR-ABL pathways, and potently inhibits FLT3-ITD/D835Y and FLT3-ITD/F691L secondary mutants. Bioorg Chem. 2024 Feb; 143:106966.
-
Zhang L, Lakkaniga NR, Bharate JB, Mcconnell N, Wang X, Kharbanda A, Leung YK, Frett B, Shah NP, Li HY. Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor. Eur J Med Chem. 2021 Dec 05; 225:113776.
-
Garitano-Trojaola A, Sancho A, G?tz R, Eiring P, Walz S, Jetani H, Gil-Pulido J, Da Via MC, Teufel E, Rhodes N, Haertle L, Arellano-Viera E, Tibes R, Rosenwald A, Rasche L, Hudecek M, Sauer M, Groll J, Einsele H, Kraus S, Kort?m MK. Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia. Commun Biol. 2021 06 25; 4(1):799.
-
Iacobucci I, Wen J, Meggendorfer M, Choi JK, Shi L, Pounds SB, Carmichael CL, Masih KE, Morris SM, Lindsley RC, Janke LJ, Alexander TB, Song G, Qu C, Li Y, Payne-Turner D, Tomizawa D, Kiyokawa N, Valentine M, Valentine V, Basso G, Locatelli F, Enemark EJ, Kham SKY, Yeoh AEJ, Ma X, Zhou X, Sioson E, Rusch M, Ries RE, Stieglitz E, Hunger SP, Wei AH, To LB, Lewis ID, D'Andrea RJ, Kile BT, Brown AL, Scott HS, Hahn CN, Marlton P, Pei D, Cheng C, Loh ML, Ebert BL, Meshinchi S, Haferlach T, Mullighan CG. Genomic subtyping and therapeutic targeting of acute erythroleukemia. Nat Genet. 2019 04; 51(4):694-704.
-
Bharate JB, McConnell N, Naresh G, Zhang L, Lakkaniga NR, Ding L, Shah NP, Frett B, Li HY. Rational Design, Synthesis and Biological Evaluation of Pyrimidine-4,6-diamine derivatives as Type-II inhibitors of FLT3 Selective Against c-KIT. Sci Rep. 2018 02 27; 8(1):3722.
-
Frett B, McConnell N, Smith CC, Wang Y, Shah NP, Li HY. Computer aided drug discovery of highly ligand efficient, low molecular weight imidazopyridine analogs as FLT3 inhibitors. Eur J Med Chem. 2015 Apr 13; 94:123-31.
-
Mathias TJ, Natarajan K, Shukla S, Doshi KA, Singh ZN, Ambudkar SV, Baer MR. The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations. Invest New Drugs. 2015 Apr; 33(2):300-9.
|
People People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|